IMAGING IN THE DIAGNOSIS AND MANAGEMENT OF PATIENTSWITH VESTIBULAR SCHWANNOMAS
TARGET POPULATION: Adult patients with vestibular schwannomas.
RECOMMENDATION: Level 3:
The degree of lateral internal auditory canal involvement by tumor adversely affects facial nerve and hearing outcomes and should be emphasized when interpreting imaging for preoperative planning. QUESTION 6: How should patients with neurofibromatosis type 2 (NF2) and vestibular schwannoma be imaged and over what follow-up period? TARGET POPULATION: Adult patients with NF2 and vestibular schwannomas. RECOMMENDATION: Level 3: In general, vestibular schwannomas associated with NF2 should be imaged (similar to sporadic schwannomas) with the following caveats: 1. More frequent imaging may be adopted in NF2 patients because of a more variable growth rate for vestibular schwannomas, and annual imaging may ensue once the growth rate is established. 2. In NF2 patients with bilateral vestibular schwannomas, growth rate of a vestibular schwannoma may increase after resection of the contralateral tumor, and therefore, more frequent imaging may be indicated, based on the nonoperated tumor's historical rate of growth. 3. Careful consideration should be given to whether contrast is necessary in followup studies or if high-resolution T2 (including CISS or FIESTA-type sequences) MRI may adequately characterize changes in lesion size instead. QUESTION 7: How long should vestibular schwannomas be imaged after surgery, including after gross-total, near-total, and subtotal resection? TARGET POPULATION: Adult patients with vestibular schwannomas followed after surgery. RECOMMENDATION: Level 3: For patients receiving gross total resection, a postoperative MRI may be considered to document the surgical impression and may occur as late as 1 yr after surgery. For patients not receiving gross total resection, more frequent surveillance scans are suggested; annual MRI scans may be reasonable for 5 yr. Imaging followup should be adjusted accordingly for continued surveillance if any change in nodular enhancement is demonstrated.
The full guideline can be found at https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_5. www.neurosurgery-online.com V estibular schwannomas (VSs) are the most common intracranial nerve sheath tumor, with imaging playing a critical role in their management. The following review was performed in order to provide a set of evidence-based recommendations for the use of imaging in the management of patients with VSs.
ABBREVIATIONS: 3-D, 3-dimensional; CISS, constructive interference in steady state; FIESTA, fast imaging employing steady-state acquisition; MPRAGE, magnetization prepared rapid acquisition gradient echo; MRI, magnetic resonance imaging; NF2, neurofibromatosis type 2; VS, vestibular schwannoma
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_5) and in the methodology article (https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_1) of this guideline series. A total of 2070 citations, which were identified through a search of PubMed and Cochrane Central, were manually reviewed. Two independent reviewers evaluated and abstracted full-text data for each article. Citations focused on the imaging of VSs in adult patients largely in the magnetic resonance imaging (MRI) era (January 1, 1990 to December 31, 2014), published in English, were considered; citations meeting the inclusion criteria were reviewed in full and used for evidence tables and to create recommendations. The selected studies were classified according to criteria for evidence on diagnosis as detailed in the Joint Guidelines Committee guideline development methodology (https://www.cns.org/guidelines/guideline-procedures-policies/guideline -development-methodology). Bias was addressed by stratifying by evidence quality, acknowledging inherent selection bias in any imaging study.
RESULTS
Excellent preoperative identification and surveillance of VSs can be achieved using 3-D T2 constructive interference in steady state or postcontrast 3-D T1 magnetization prepared rapid acquisition gradient echo MRI. Class III evidence supports that the course of the facial nerve may be determined on preoperative MRI, especially with T2-weighted sequences and with tractography reconstruction. Class III evidence supports the conclusion that about two-thirds of patients with VSs may not exhibit measurable growth, while one-third demonstrate growth, defined variably as either any increase in size or a change in diameter >2 mm. Intrameatal tumors are less likely to grow. Cystic vestibular may demonstrate rapid growth, symptomatic deterioration, and be associated with lower rates of complete resection, worse short-term facial nerve outcomes, and unpredictable response to radiation. Class III evidence supports the conclusion that lateral involvement correlated with decreased facial nerve and hearing function; Class III evidence also supports the conclusion that neurofibromatosis type 2-associated VSs demonstrate unique growth patterns and growth rates. Continued surveillance is required in patients without a complete resection.
DISCUSSION
VSs are usually imaged with MRI, with contrast-enhanced scans considered to be the gold standard for the initial evaluation and postoperative assessment of recurrence or residual tumors. The use of high-resolution T2 sequences to follow VSs, however, is supported by class II evidence. Specific imaging features with clinical application-though supported by class III evidenceinclude, in addition to size and the presence of hydrocephalus, the extent of lateral extension in the internal auditory canal and the presence of cystic intratumoral contents.
Imaging is a crucial tool in the evaluation and management of patients with VSs, with MRI supplanting computed tomography nearly entirely. Bias as to which patients are treated conservatively and interobserver variation in the definition of growth rate may underlie differential reporting; automated size calculations may remedy this. Higher-resolution T2 sequences and refinements in diffusion tensor imaging may render facial nerve identification even more reliable, providing valuable information to the surgeon, and in turn the patient, preoperatively.
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